EGFR and esophageal squamous cell carcinoma: In their in vitro and in vivo model study, Hoi and his team found that chemotherapy upregulated the expression of PD-L1 in ESCC by activating the EGFR/ERK pathway, suggesting that anti-PD-L1 immunotherapy combined with conventional chemotherapy could achieve a better therapeutic effect (5).